BR0307544A - Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos - Google Patents
Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentosInfo
- Publication number
- BR0307544A BR0307544A BR0307544A BR0307544A BR0307544A BR 0307544 A BR0307544 A BR 0307544A BR 0307544 A BR0307544 A BR 0307544A BR 0307544 A BR0307544 A BR 0307544A BR 0307544 A BR0307544 A BR 0307544A
- Authority
- BR
- Brazil
- Prior art keywords
- phosphorus
- composition
- components
- well
- treatment methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 title abstract 2
- 229910052698 phosphorus Inorganic materials 0.000 title abstract 2
- 239000011574 phosphorus Substances 0.000 title abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- -1 heteroaliphatic Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35325202P | 2002-02-01 | 2002-02-01 | |
| US42692802P | 2002-11-15 | 2002-11-15 | |
| US42838302P | 2002-11-22 | 2002-11-22 | |
| US43393002P | 2002-12-17 | 2002-12-17 | |
| PCT/US2003/003030 WO2003064383A2 (en) | 2002-02-01 | 2003-02-03 | Phosphorus-containing compounds & uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0307544A true BR0307544A (pt) | 2004-12-07 |
Family
ID=27671080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0307544A BR0307544A (pt) | 2002-02-01 | 2003-02-03 | Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos |
Country Status (16)
Families Citing this family (302)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040073294A1 (en) | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
| US7432277B2 (en) | 2002-02-01 | 2008-10-07 | Araid Gene Therapeutics, Inc. | Phosphorus-containing macrocycles |
| PL216224B1 (pl) | 2002-02-01 | 2014-03-31 | Ariad Pharmaceuticals | Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie |
| BR0309557A (pt) | 2002-04-26 | 2005-03-01 | Gilead Sciences Inc | Inibidores da transcriptase reversa não nucleosìdeos |
| EP2277898A3 (en) * | 2002-07-16 | 2011-06-01 | Biotica Technology Limited | Rapamycin analogues |
| US8980870B2 (en) * | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
| US20040202789A1 (en) * | 2003-03-31 | 2004-10-14 | Council Of Scientific And Industrila Research | Process for preparing thin film solids |
| US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| AU2004233897A1 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
| EA014685B1 (ru) | 2003-04-25 | 2010-12-30 | Джилид Сайэнс, Инк. | Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе |
| WO2004096236A2 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Immunomodulator phosphonate conjugates |
| US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
| US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
| US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
| US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
| WO2004096285A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
| ES2316995T3 (es) * | 2003-07-08 | 2009-04-16 | Novartis Ag | Uso de rapamicina y derivados de rapamicida para el tratamiento de la perdida osea. |
| WO2005016252A2 (en) * | 2003-07-11 | 2005-02-24 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing macrocycles |
| US20050049693A1 (en) * | 2003-08-25 | 2005-03-03 | Medtronic Vascular Inc. | Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease |
| EP1678321A1 (en) | 2003-10-24 | 2006-07-12 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds |
| US7427624B2 (en) | 2003-10-24 | 2008-09-23 | Gilead Sciences, Inc. | Purine nucleoside phosphorylase inhibitory phosphonate compounds |
| US7432273B2 (en) | 2003-10-24 | 2008-10-07 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
| WO2005049021A1 (en) * | 2003-11-03 | 2005-06-02 | Oy Helsinki Transplantation R & D Ltd | Materials and methods for inhibiting neointimal hyperplasia |
| AR046194A1 (es) | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
| GB0327840D0 (en) * | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| US7294123B2 (en) * | 2003-12-17 | 2007-11-13 | Corris Neurovascular, Inc. | Activatable bioactive vascular occlusive device and method of use |
| US20050137568A1 (en) * | 2003-12-17 | 2005-06-23 | Jones Donald K. | Activatable bioactive implantable medical device and method of use |
| JP4744863B2 (ja) * | 2003-12-17 | 2011-08-10 | コドマン・アンド・シャートレフ・インコーポレイテッド | 活性化可能で生体活性の移植可能な医療装置およびその使用方法 |
| NZ547907A (en) | 2003-12-22 | 2010-07-30 | Gilead Sciences Inc | 4'-Substituted carbovir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity |
| US20050187608A1 (en) * | 2004-02-24 | 2005-08-25 | O'hara Michael D. | Radioprotective compound coating for medical devices |
| US7247159B2 (en) | 2004-04-08 | 2007-07-24 | Cordis Neurovascular, Inc. | Activatable bioactive vascular occlusive device |
| RU2006144809A (ru) * | 2004-05-17 | 2008-06-27 | Новартис АГ (CH) | Комбинация органических соединений |
| DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| UA88313C2 (ru) | 2004-07-27 | 2009-10-12 | Гилиад Сайенсиз, Инк. | Фосфонатные аналоги соединений ингибиторов вич |
| US8075904B2 (en) * | 2004-08-11 | 2011-12-13 | California Institute Of Technology | High aspect ratio template and method for producing same for central and peripheral nerve repair |
| US8263102B2 (en) | 2004-09-28 | 2012-09-11 | Atrium Medical Corporation | Drug delivery coating for use with a stent |
| US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
| US9801913B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Barrier layer |
| US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
| US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
| MX2007003790A (es) * | 2004-09-30 | 2007-05-24 | Ariad Gene Therapeutics Inc | Metodo de tratamiento. |
| AU2006210572B2 (en) | 2005-02-03 | 2011-08-04 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
| US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
| US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| GB0504995D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Use of a compound |
| GB0504994D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| GB0507918D0 (en) | 2005-04-19 | 2005-05-25 | Novartis Ag | Organic compounds |
| AU2006254397A1 (en) * | 2005-05-31 | 2006-12-07 | Novartis Ag | Combination of HMG-CoA reductase inhibitors and mTOR inhibitors |
| US20070071754A1 (en) * | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Method to ameliorate inflammation |
| US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| CA2626030A1 (en) * | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
| ES2944067T3 (es) | 2005-10-26 | 2023-06-19 | Novartis Ag | Uso de anticuerpos anti il-1beta |
| AU2006311877A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth Llc | Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272 |
| EA015922B1 (ru) * | 2005-11-14 | 2011-12-30 | Ариад Фармасьютикалз, Инк. | ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ |
| NO20220050A1 (no) | 2005-11-21 | 2008-08-12 | Novartis Ag | Neuroendokrin tumorbehandling |
| SI2495016T1 (sl) | 2005-12-23 | 2020-04-30 | Ariad Pharmaceuticals, Inc. | Biciklične heteroarilne spojine |
| DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
| GB0609963D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
| EP2076266A2 (en) * | 2006-05-31 | 2009-07-08 | The Board of Trustees of the Leland Stanford Junior University | Method of treating inflammatory diseases using tyroskine kinase inhibitors |
| EP2032168A4 (en) * | 2006-06-02 | 2010-12-29 | Ariad Pharma Inc | COMBINED THERAPY BASED ON CAPECITABINE |
| WO2008016633A2 (en) * | 2006-08-02 | 2008-02-07 | Ariad Gene Therapeutics, Inc. | Combination therapy |
| WO2008033956A2 (en) | 2006-09-13 | 2008-03-20 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
| US10695327B2 (en) | 2006-09-13 | 2020-06-30 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
| US8088789B2 (en) | 2006-09-13 | 2012-01-03 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
| SG175609A1 (en) | 2006-10-09 | 2011-11-28 | Takeda Pharmaceutical | Kinase inhibitors |
| US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
| US8642031B2 (en) * | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
| US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
| WO2008057344A2 (en) | 2006-11-06 | 2008-05-15 | Atrium Medical Corporation | Coated surgical mesh |
| AU2007319825B2 (en) | 2006-11-14 | 2014-01-23 | Ariad Pharmaceuticals, Inc. | Oral formulations |
| US8466096B2 (en) * | 2007-04-26 | 2013-06-18 | Afton Chemical Corporation | 1,3,2-dioxaphosphorinane, 2-sulfide derivatives for use as anti-wear additives in lubricant compositions |
| CA3213888A1 (en) | 2007-05-29 | 2008-12-04 | Novartis Ag | New indications for anti-il-i-beta therapy |
| US8142702B2 (en) * | 2007-06-18 | 2012-03-27 | Molecular Imprints, Inc. | Solvent-assisted layer formation for imprint lithography |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| WO2009054001A1 (en) * | 2007-10-22 | 2009-04-30 | Biocon Limited | A pharmaceutical composition and a process thereof |
| WO2009073193A2 (en) * | 2007-12-03 | 2009-06-11 | The Johns Hopkins University | Methods of synthesis and use of chemospheres |
| US9002344B2 (en) * | 2007-12-05 | 2015-04-07 | Microsoft Technology Licensing, Llc | Phone content service |
| US8921642B2 (en) | 2008-01-11 | 2014-12-30 | Massachusetts Eye And Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
| US20090253733A1 (en) * | 2008-04-02 | 2009-10-08 | Biointeractions, Ltd. | Rapamycin carbonate esters |
| US20110098241A1 (en) * | 2008-04-14 | 2011-04-28 | Poniard Pharmaceuticals, Inc. | Rapamycin analogs as anti-cancer agents |
| HUE035029T2 (en) | 2008-05-21 | 2018-03-28 | Ariad Pharma Inc | Kinase inhibitor phosphorus derivatives |
| KR20180128078A (ko) | 2008-06-17 | 2018-11-30 | 와이어쓰 엘엘씨 | Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
| EA018308B1 (ru) | 2008-07-08 | 2013-07-30 | Джилид Сайэнс, Инк. | Соли соединений ингибиторов вич |
| KR101138294B1 (ko) * | 2008-09-24 | 2012-04-25 | 김형일 | 혈관벽 임시 골격용 생분해성 블랜드 |
| WO2010056311A1 (en) | 2008-11-12 | 2010-05-20 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
| WO2010101622A1 (en) * | 2009-03-02 | 2010-09-10 | Merck & Co. | Lung cancer treatment |
| JP5719347B2 (ja) | 2009-04-16 | 2015-05-20 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 癌治療のための組成物及び方法 |
| WO2011002887A1 (en) | 2009-07-02 | 2011-01-06 | Schering Corporation | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS |
| US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| US10485792B2 (en) | 2009-08-26 | 2019-11-26 | Hadasit Medical Research Services & Development Limited | Sustained release delivery systems for the prevention and treatment of head and neck cancers |
| WO2011041152A1 (en) | 2009-09-30 | 2011-04-07 | Schering Corporation | Novel compounds that are erk inhibitors |
| CN102574852B (zh) | 2009-10-23 | 2014-06-25 | 伊莱利利公司 | Akt抑制剂 |
| KR20120115237A (ko) | 2009-10-30 | 2012-10-17 | 어리어드 파마슈티칼스, 인코포레이티드 | 암 치료 방법 및 조성물 |
| EP2552428A1 (en) | 2010-03-30 | 2013-02-06 | Novartis AG | Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling |
| WO2012009707A2 (en) | 2010-07-16 | 2012-01-19 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
| BR112013004012B1 (pt) | 2010-08-20 | 2021-03-23 | Novartis Ag | Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| US20140066439A1 (en) | 2010-11-10 | 2014-03-06 | Katholieke Universiteit Leuen, K.U.Leuven R&D | Osteoclast activity |
| PL2455104T3 (pl) | 2010-11-19 | 2013-12-31 | Univ Freiburg | Bio-funkcjonalizowane reagujące na bodziec rozpuszczalne hydrożele PEG |
| IN2013MN02170A (US20030220297A1-20031127-C00074.png) | 2011-04-21 | 2015-06-12 | Piramal Entpr Ltd | |
| US8901142B2 (en) | 2011-07-26 | 2014-12-02 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds as mTOR inhibitors |
| US8716363B2 (en) | 2011-09-28 | 2014-05-06 | Globus Medical, Inc. | Biodegradable putty compositions and implant devices, methods, and kits relating to the same |
| EP2589383A1 (en) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
| LT2782584T (lt) | 2011-11-23 | 2021-09-10 | Therapeuticsmd, Inc. | Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| WO2013082282A1 (en) | 2011-12-02 | 2013-06-06 | lNOVARTIS AG | Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease. |
| SG11201402739YA (en) | 2011-12-05 | 2014-06-27 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
| EP3590538A1 (en) | 2011-12-05 | 2020-01-08 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) |
| CN104105690A (zh) | 2011-12-05 | 2014-10-15 | 诺华股份有限公司 | 作为雄激素受体拮抗剂的环状尿素衍生物 |
| CA2860676A1 (en) | 2012-01-09 | 2013-07-18 | Novartis Ag | Organic compositions to treat beta-catenin-related diseases |
| CN110404062A (zh) | 2012-03-23 | 2019-11-05 | 昆士兰大学 | 免疫调节剂及其用途 |
| US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| TW201408682A (zh) | 2012-08-22 | 2014-03-01 | Chunghwa Chemical Synthesis & Biotech Co Ltd | 高轉化率之４２－（二甲基亞磷醯）雷帕霉素的製備方法 |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| EP3360870A1 (en) | 2013-02-19 | 2018-08-15 | Novartis AG | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
| RU2708032C2 (ru) | 2013-02-20 | 2019-12-03 | Новартис Аг | ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| CN105073112B (zh) | 2013-03-13 | 2017-12-29 | 参天制药株式会社 | 睑板腺功能障碍的治疗剂 |
| NZ710929A (en) | 2013-03-15 | 2018-02-23 | Novartis Ag | Antibody drug conjugates |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| WO2014184734A1 (en) | 2013-05-14 | 2014-11-20 | Novartis Ag | Markers associated with mtor inhibition |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| CA2938626A1 (en) | 2013-07-26 | 2015-01-29 | John Rothman | Compositions to improve the therapeutic benefit of bisantrene |
| WO2015044854A1 (en) | 2013-09-24 | 2015-04-02 | Novartis Ag | Markers associated with mtor inhibition |
| US20150140036A1 (en) | 2013-11-13 | 2015-05-21 | Novartis Institutes For Biomedical Research, Inc. | Low, immune enhancing, dose mtor inhibitors and uses thereof |
| EP2878312A1 (en) | 2013-12-02 | 2015-06-03 | Albert-Ludwigs-Universität Freiburg | Reversible PEGylation of nanocarriers |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| CN116478927A (zh) | 2013-12-19 | 2023-07-25 | 诺华股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| EP3089737B1 (en) | 2013-12-31 | 2021-11-03 | Rapamycin Holdings, LLC | Oral rapamycin nanoparticle preparations and use |
| US9815813B2 (en) | 2014-01-17 | 2017-11-14 | Novartis Ag | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2015107493A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CU24481B1 (es) | 2014-03-14 | 2020-03-04 | Immutep Sas | Moléculas de anticuerpo que se unen a lag-3 |
| EP3811970A1 (en) | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| SG10202109752XA (en) | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| CA2950589A1 (en) | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
| MA40240B1 (fr) | 2014-06-19 | 2019-03-29 | Ariad Pharma Inc | Composés hétéroaryle d'inhibition de la kinase |
| EP3169708B1 (en) | 2014-07-16 | 2019-03-20 | Dana-Farber Cancer Institute Inc. et Al. | Her3 inhibition in low-grade serous ovarian cancers |
| WO2016014576A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
| US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
| CN106659790A (zh) | 2014-08-12 | 2017-05-10 | 诺华股份有限公司 | 抗cdh6抗体药物缀合物 |
| JP6919118B2 (ja) | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | ＧＦＲα−４キメラ抗原受容体を用いる癌の治療 |
| RU2724999C2 (ru) | 2014-08-19 | 2020-06-29 | Новартис Аг | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей |
| JP6681905B2 (ja) | 2014-09-13 | 2020-04-15 | ノバルティス アーゲー | Ａｌｋ阻害剤の併用療法 |
| WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| AU2015327868A1 (en) | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| WO2016057705A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CR20170143A (es) | 2014-10-14 | 2017-06-19 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| KR20170084202A (ko) | 2014-11-14 | 2017-07-19 | 노파르티스 아게 | 항체 약물 접합체 |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| US10377818B2 (en) | 2015-01-30 | 2019-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating glioma |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| MX2017012295A (es) | 2015-03-25 | 2018-01-09 | Novartis Ag | Derivados formilados n-heterociclicos como inhibidores de fgfr4. |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| DK3280729T3 (da) | 2015-04-08 | 2022-07-25 | Novartis Ag | Cd20-behandlinger, cd22-behandlinger og kombinationsbehandlinger med en cd19-kimær antigenreceptor (car)-udtrykkende celle |
| AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| US20180298068A1 (en) | 2015-04-23 | 2018-10-18 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CN107847491A (zh) | 2015-05-20 | 2018-03-27 | 诺华公司 | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 |
| EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
| EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| WO2016203406A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| WO2016203405A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| CN109476722A (zh) | 2015-07-21 | 2019-03-15 | 诺华股份有限公司 | 用于改善免疫细胞的功效和扩张的方法 |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| WO2017019896A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
| US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| SG11201803520PA (en) | 2015-11-03 | 2018-05-30 | Janssen Biotech Inc | Antibodies specifically binding pd-1 and their uses |
| IL258574B1 (en) | 2015-11-11 | 2024-09-01 | Novartis Ag | Uses of myostatin antagonists, combinations containing them and their uses |
| AU2016369537B2 (en) | 2015-12-17 | 2024-03-14 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
| MA44140A (fr) | 2015-12-22 | 2021-05-19 | Dana Farber Cancer Inst Inc | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
| WO2017150039A1 (ja) * | 2016-02-29 | 2017-09-08 | 富士フイルム株式会社 | 平版印刷版原版及び平版印刷版の製版方法 |
| KR20180118175A (ko) | 2016-03-04 | 2018-10-30 | 노파르티스 아게 | 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도 |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| DK3452465T3 (da) | 2016-05-04 | 2021-02-08 | Genoscience Pharma | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme |
| RU2744988C2 (ru) | 2016-06-14 | 2021-03-17 | Новартис Аг | Соединения и композиции для подавления активности shp2 |
| CA3031542A1 (en) | 2016-07-20 | 2018-01-25 | University Of Utah Research Foundation | Cd229 car t cells and methods of use thereof |
| EP3515475B1 (en) | 2016-09-21 | 2024-05-01 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use |
| JP2019536471A (ja) | 2016-09-27 | 2019-12-19 | セロ・セラピューティクス・インコーポレイテッドＣＥＲＯ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | キメラエンガルフメント受容体分子 |
| TW202340473A (zh) | 2016-10-07 | 2023-10-16 | 瑞士商諾華公司 | 利用嵌合抗原受體之癌症治療 |
| TW201825090A (zh) | 2016-11-23 | 2018-07-16 | 瑞士商諾華公司 | 增強免疫反應之方法 |
| WO2018163051A1 (en) | 2017-03-06 | 2018-09-13 | Novartis Ag | Methods of treatment of cancer with reduced ubb expression |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
| EP3630162A1 (en) | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use |
| AU2018274216A1 (en) | 2017-05-24 | 2019-12-12 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| EP3634584B1 (en) | 2017-06-09 | 2024-09-18 | Providence Health & Services - Oregon | Tumor-infiltrating t-cells for use in the treatment of cancer |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
| SG11201912473PA (en) | 2017-06-22 | 2020-01-30 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| PL3661937T3 (pl) | 2017-08-01 | 2021-12-20 | Gilead Sciences, Inc. | Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych |
| MA50245A (fr) | 2017-09-11 | 2020-07-22 | Krouzon Pharmaceuticals Inc | Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2 |
| AU2018341244A1 (en) | 2017-09-26 | 2020-03-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules and methods of use |
| UY37900A (es) | 2017-09-26 | 2019-04-30 | Novartis Ag | Nuevos derivados de rapamicina |
| WO2019108900A1 (en) | 2017-11-30 | 2019-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| EP3715343B1 (en) | 2017-12-21 | 2024-02-14 | Shenzhen TargetRx, Inc. | Diphenylaminopyrimidine compound for inhibiting kinase activity |
| JP7085242B2 (ja) | 2017-12-21 | 2022-06-16 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | キナーゼ活性を阻害するためのアリールホスフィンオキシド |
| US20200368268A1 (en) | 2018-01-08 | 2020-11-26 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| AU2019215031A1 (en) | 2018-01-31 | 2020-08-20 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
| US20200399383A1 (en) | 2018-02-13 | 2020-12-24 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| CN112218887A (zh) | 2018-03-28 | 2021-01-12 | 森罗治疗公司 | 细胞免疫疗法组合物及其用途 |
| EP3774906A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| CN112218886A (zh) | 2018-03-28 | 2021-01-12 | 森罗治疗公司 | 嵌合吞噬受体的表达载体、基因修饰的宿主细胞及其用途 |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| JP7361727B2 (ja) | 2018-05-24 | 2023-10-16 | ヤンセン バイオテツク，インコーポレーテツド | Ｐｓｍａ結合剤及びその使用 |
| US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| US11492409B2 (en) | 2018-06-01 | 2022-11-08 | Novartis Ag | Binding molecules against BCMA and uses thereof |
| TW202016139A (zh) | 2018-06-13 | 2020-05-01 | 瑞士商諾華公司 | Bcma 嵌合抗原受體及其用途 |
| JOP20210001A1 (ar) | 2018-07-10 | 2021-01-05 | Novartis Ag | مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| KR102643582B1 (ko) | 2018-07-25 | 2024-03-05 | 어드밴스드 엑셀러레이터 어플리케이션즈 | 안정한 농축 방사성 핵종 복합체 용액 |
| EP3853234A1 (en) | 2018-09-18 | 2021-07-28 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| CN113382986A (zh) | 2018-09-25 | 2021-09-10 | 黑钻治疗公司 | 酪氨酸激酶抑制剂组合物、其制备方法和使用方法 |
| US20210346527A1 (en) | 2018-09-25 | 2021-11-11 | Advanced Accelerator Applications (Italy) Srl | Combination Therapy |
| CN113164776A (zh) | 2018-09-25 | 2021-07-23 | 黑钻治疗公司 | 酪氨酸激酶抑制剂组合物、其制备方法和使用方法 |
| EP3856779A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd22 chimeric antigen receptor (car) therapies |
| EP3856782A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| KR20210068473A (ko) | 2018-09-29 | 2021-06-09 | 노파르티스 아게 | Shp2 활성 억제용 화합물의 제조 방법 |
| EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| CN113490528A (zh) | 2019-02-15 | 2021-10-08 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| MX2021011289A (es) | 2019-03-22 | 2021-11-03 | Sumitomo Pharma Oncology Inc | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. |
| CA3145864A1 (en) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
| CN110407872A (zh) * | 2019-07-25 | 2019-11-05 | 江苏好收成韦恩农化股份有限公司 | 烷基氯化膦酸单烷酯联产高纯度三氯氧磷的方法 |
| MX2022001952A (es) | 2019-08-15 | 2022-06-02 | Black Diamond Therapeutics Inc | Compuestos de alquinil quinazolina. |
| EP4031578A1 (en) | 2019-09-18 | 2022-07-27 | Novartis AG | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| WO2021067875A1 (en) | 2019-10-03 | 2021-04-08 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| US20230093147A1 (en) | 2020-03-09 | 2023-03-23 | President And Fellows Of Harvard College | Methods and compositions relating to improved combination therapies |
| WO2021195206A1 (en) | 2020-03-24 | 2021-09-30 | Black Diamond Therapeutics, Inc. | Polymorphic forms and related uses |
| WO2021217508A1 (en) | 2020-04-29 | 2021-11-04 | Novartis Ag | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2α AND THEIR METHODS OF USE |
| CA3180060A1 (en) | 2020-05-29 | 2021-12-02 | Zongmin ZHAO | Living cells engineered with polyphenol-functionalized biologically active nanocomplexes |
| AU2021288224A1 (en) | 2020-06-11 | 2023-01-05 | Novartis Ag | ZBTB32 inhibitors and uses thereof |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| US20230235077A1 (en) | 2020-06-24 | 2023-07-27 | The General Hospital Corporation | Materials and methods of treating cancer |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2022036285A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase |
| WO2022036287A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
| WO2022036265A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
| WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
| TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法 |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| WO2022140472A1 (en) | 2020-12-22 | 2022-06-30 | Nikang Therapeutics, Inc. | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway |
| WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| MX2023008909A (es) | 2021-01-28 | 2023-10-23 | Janssen Biotech Inc | Proteínas de unión a psma y usos de estas. |
| WO2022170052A1 (en) | 2021-02-05 | 2022-08-11 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof |
| CN117203223A (zh) | 2021-02-26 | 2023-12-08 | 凯洛尼亚疗法有限公司 | 淋巴细胞靶向慢病毒载体 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| PE20240327A1 (es) | 2021-04-13 | 2024-02-22 | Nuvalent Inc | Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr |
| EP4323350A1 (en) | 2021-04-14 | 2024-02-21 | Monte Rosa Therapeutics AG | Isoindolinone compounds |
| EP4323349A1 (en) | 2021-04-14 | 2024-02-21 | Monte Rosa Therapeutics AG | Isoindolinone amide compounds useful to treat diseases associated with gspt1 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CA3218590A1 (en) | 2021-06-07 | 2022-12-15 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
| EP4370522A1 (en) | 2021-07-14 | 2024-05-22 | Nikang Therapeutics, Inc. | Alkylidene derivatives as kras inhibitors |
| EP4370160A1 (en) | 2021-07-15 | 2024-05-22 | President And Fellows Of Harvard College | Compositions and methods relating to cells with adhered particles |
| EP4376874A1 (en) | 2021-07-28 | 2024-06-05 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| WO2023192801A1 (en) | 2022-03-28 | 2023-10-05 | Nikang Therapeutics, Inc. | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2023240024A1 (en) | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
| WO2024023666A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Crystalline forms of an akr1c3 dependent kars inhibitor |
| WO2024102849A1 (en) | 2022-11-11 | 2024-05-16 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
Family Cites Families (201)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3976071A (en) | 1974-01-07 | 1976-08-24 | Dynatech Corporation | Methods of improving control of release rates and products useful in same |
| US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
| US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US4335094A (en) | 1979-01-26 | 1982-06-15 | Mosbach Klaus H | Magnetic polymer particles |
| US4345588A (en) | 1979-04-23 | 1982-08-24 | Northwestern University | Method of delivering a therapeutic agent to a target capillary bed |
| US4357925A (en) | 1980-12-17 | 1982-11-09 | The Bendix Corporation | Distributor injection pump for diesel engines |
| US4501726A (en) | 1981-11-12 | 1985-02-26 | Schroeder Ulf | Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof |
| US5206159A (en) | 1984-11-01 | 1993-04-27 | Miles Inc., As Legal Successor By Merger With Technicon Instruments Corp. | Polymer particles containing colloidal iron oxide granules for use as a magnetically responsive reagent carrier |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| GB8601100D0 (en) | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
| US4871716A (en) | 1986-02-04 | 1989-10-03 | University Of Florida | Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof |
| US5000185A (en) | 1986-02-28 | 1991-03-19 | Cardiovascular Imaging Systems, Inc. | Method for intravascular two-dimensional ultrasonography and recanalization |
| US4832686A (en) | 1986-06-24 | 1989-05-23 | Anderson Mark E | Method for administering interleukin-2 |
| US5069216A (en) | 1986-07-03 | 1991-12-03 | Advanced Magnetics Inc. | Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract |
| JPS6390534A (ja) | 1986-10-06 | 1988-04-21 | Hitachi Ltd | アルカリ可溶性ラダ−シリコ−ン重合体 |
| JPS63101427A (ja) | 1986-10-17 | 1988-05-06 | Hitachi Ltd | アルカリ可溶性ラダ−シリコ−ン |
| US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
| US4837311A (en) | 1987-06-22 | 1989-06-06 | Hoffman-La Roche Inc. | Anti-retroviral compounds |
| US4894231A (en) | 1987-07-28 | 1990-01-16 | Biomeasure, Inc. | Therapeutic agent delivery system |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| JPH01126474U (US20030220297A1-20031127-C00074.png) * | 1988-02-22 | 1989-08-29 | ||
| US6146358A (en) * | 1989-03-14 | 2000-11-14 | Cordis Corporation | Method and apparatus for delivery of therapeutic agent |
| US4936281A (en) | 1989-04-13 | 1990-06-26 | Everest Medical Corporation | Ultrasonically enhanced RF ablation catheter |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| US5182293A (en) | 1989-11-13 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Treatment of multi-drug resistant tumors with pyridyloxazole-2-ones |
| US5067491A (en) | 1989-12-08 | 1991-11-26 | Becton, Dickinson And Company | Barrier coating on blood contacting devices |
| EP0441516B1 (en) * | 1990-02-08 | 1995-03-29 | Howmedica Inc. | Inflatable stent |
| US5545208A (en) * | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
| US6004346A (en) | 1990-02-28 | 1999-12-21 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
| US5195417A (en) | 1990-04-26 | 1993-03-23 | Northern Telecom Limited | Registration of artwork panels in the manufacture of printed circuit boards |
| WO1991017724A1 (en) | 1990-05-17 | 1991-11-28 | Harbor Medical Devices, Inc. | Medical device polymer |
| ATE123658T1 (de) | 1990-06-15 | 1995-06-15 | Cortrak Medical Inc | Vorrichtung zur abgabe von medikamenten. |
| US5112457A (en) | 1990-07-23 | 1992-05-12 | Case Western Reserve University | Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants |
| US5163952A (en) | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
| US5378696A (en) | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
| US5130307A (en) | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
| US5484584A (en) | 1990-10-02 | 1996-01-16 | Board Of Regents, The University Of Texas System | Therapeutic and diagnostic use of modified polymeric microcapsules |
| JPH06502536A (ja) * | 1990-10-09 | 1994-03-24 | メルク エンド カンパニー インコーポレーテッド | 有機化合物の新規生物学的リン酸化方法 |
| US5893840A (en) | 1991-01-04 | 1999-04-13 | Medtronic, Inc. | Releasable microcapsules on balloon catheters |
| US5368557A (en) | 1991-01-11 | 1994-11-29 | Baxter International Inc. | Ultrasonic ablation catheter device having multiple ultrasound transmission members |
| WO1993013663A1 (en) | 1992-01-17 | 1993-07-22 | Abbott Laboratories | Method of directing biosynthesis of specific polyketides |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5194447A (en) | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
| US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| DE4117782C2 (de) | 1991-05-28 | 1997-07-17 | Diagnostikforschung Inst | Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel |
| ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| US5176907A (en) | 1991-08-13 | 1993-01-05 | The Johns Hopkins University School Of Medicine | Biocompatible and biodegradable poly (phosphoester-urethanes) |
| US5356433A (en) | 1991-08-13 | 1994-10-18 | Cordis Corporation | Biocompatible metal surfaces |
| US5604294A (en) * | 1991-09-05 | 1997-02-18 | Luly; Jay R. | Macrocyclic immunomodulators |
| US5252732A (en) * | 1991-09-09 | 1993-10-12 | Merck & Co., Inc. | D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity |
| US5411550A (en) | 1991-09-16 | 1995-05-02 | Atrium Medical Corporation | Implantable prosthetic device for the delivery of a bioactive material |
| US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
| WO1993006792A1 (en) | 1991-10-04 | 1993-04-15 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
| US5464450A (en) | 1991-10-04 | 1995-11-07 | Scimed Lifesystems Inc. | Biodegradable drug delivery vascular stent |
| US5500013A (en) | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
| US5225282A (en) | 1991-12-13 | 1993-07-06 | Molecular Bioquest, Inc. | Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer |
| US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| US5876452A (en) | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
| US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| US5656297A (en) | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| US5599352A (en) | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
| ATE193652T1 (de) | 1992-03-30 | 2000-06-15 | American Home Prod | Rapamycin formulierung zur iv-injektion |
| US5288711A (en) | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
| US5283257A (en) | 1992-07-10 | 1994-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating hyperproliferative vascular disease |
| MX9304868A (es) * | 1992-08-13 | 1994-05-31 | American Home Prod | 27-hidroxirapamicina, derivados de la misma y composicion farmaceutica que la contiene. |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5434260A (en) * | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
| US5489680A (en) * | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
| US5342348A (en) | 1992-12-04 | 1994-08-30 | Kaplan Aaron V | Method and device for treating and enlarging body lumens |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| WO1994018317A1 (en) | 1993-02-12 | 1994-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
| US5310903A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
| DE69435044T2 (de) | 1993-04-23 | 2008-09-18 | Wyeth | Rapamycin - Konjugate und Antikörper |
| US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
| HUT73100A (en) | 1993-07-16 | 1996-06-28 | Harvard College | Regulated apoptosis |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5387680A (en) * | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
| US5409000A (en) | 1993-09-14 | 1995-04-25 | Cardiac Pathways Corporation | Endocardial mapping and ablation system utilizing separately controlled steerable ablation catheter with ultrasonic imaging capabilities and method |
| IL111004A (en) | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
| US5516770A (en) | 1993-09-30 | 1996-05-14 | American Home Products Corporation | Rapamycin formulation for IV injection |
| AU688782B2 (en) | 1993-09-30 | 1998-03-19 | Wyeth | Rapamycin formulations for oral administration |
| US5536729A (en) | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US5616588A (en) | 1993-09-30 | 1997-04-01 | American Home Products Corporation | Rapamycin formulation for IV injection |
| US5391730A (en) * | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
| US5463010A (en) | 1993-11-12 | 1995-10-31 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Hydrocyclosiloxane membrane prepared by plasma polymerization process |
| US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
| WO1995014023A1 (en) | 1993-11-19 | 1995-05-26 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| US5385910A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
| WO1995014865A1 (en) | 1993-11-23 | 1995-06-01 | Alliedsignal Inc. | Frictionless resilient bearing mount |
| US5525610A (en) | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US6150137A (en) | 1994-05-27 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Immunosuppressant target proteins |
| US6152141A (en) * | 1994-07-28 | 2000-11-28 | Heartport, Inc. | Method for delivery of therapeutic agents to the heart |
| US5660873A (en) | 1994-09-09 | 1997-08-26 | Bioseal, Limited Liability Corporaton | Coating intraluminal stents |
| US5891108A (en) | 1994-09-12 | 1999-04-06 | Cordis Corporation | Drug delivery stent |
| US5649977A (en) | 1994-09-22 | 1997-07-22 | Advanced Cardiovascular Systems, Inc. | Metal reinforced polymer stent |
| JP3942201B2 (ja) | 1994-11-18 | 2007-07-11 | 株式会社カネカ | フェニルポリシルセスキオキサンの製造方法 |
| US5491231A (en) * | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
| US5665591A (en) * | 1994-12-06 | 1997-09-09 | Trustees Of Boston University | Regulation of smooth muscle cell proliferation |
| US5563145A (en) * | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
| US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
| ATE544776T1 (de) | 1994-12-29 | 2012-02-15 | Massachusetts Inst Technology | Chimäre dna-bindeproteine |
| US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
| CA2178541C (en) | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
| US5609629A (en) | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
| WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| DK0833828T3 (da) * | 1995-06-09 | 2003-03-17 | Novartis Ag | Rapamycinderivater |
| WO1997002358A1 (en) | 1995-07-06 | 1997-01-23 | The Leland Stanford Junior University | Cell-free synthesis of polyketides |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| JP3324360B2 (ja) | 1995-09-25 | 2002-09-17 | 信越化学工業株式会社 | ポリシロキサン化合物及びポジ型レジスト材料 |
| US5879808A (en) | 1995-10-27 | 1999-03-09 | Alpha Metals, Inc. | Parylene polymer layers |
| US5725494A (en) | 1995-11-30 | 1998-03-10 | Pharmasonics, Inc. | Apparatus and methods for ultrasonically enhanced intraluminal therapy |
| US5735811A (en) | 1995-11-30 | 1998-04-07 | Pharmasonics, Inc. | Apparatus and methods for ultrasonically enhanced fluid delivery |
| US5728062A (en) | 1995-11-30 | 1998-03-17 | Pharmasonics, Inc. | Apparatus and methods for vibratory intraluminal therapy employing magnetostrictive transducers |
| CA2199890C (en) * | 1996-03-26 | 2002-02-05 | Leonard Pinchuk | Stents and stent-grafts having enhanced hoop strength and methods of making the same |
| US5928145A (en) | 1996-04-25 | 1999-07-27 | The Johns Hopkins University | Method of magnetic resonance imaging and spectroscopic analysis and associated apparatus employing a loopless antenna |
| US5951586A (en) | 1996-05-15 | 1999-09-14 | Medtronic, Inc. | Intraluminal stent |
| EP0937082A2 (en) | 1996-07-12 | 1999-08-25 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| US6168695B1 (en) | 1999-07-12 | 2001-01-02 | Daniel J. Woodruff | Lift and rotate assembly for use in a workpiece processing station and a method of attaching the same |
| JP2001500126A (ja) | 1996-09-09 | 2001-01-09 | アメリカン・ホーム・プロダクツ・コーポレイション | アルキル化ラパマイシン誘導体 |
| AU4246197A (en) | 1996-09-09 | 1998-03-26 | American Home Products Corporation | Rapamycin derivatives with unnatural stereochemistries |
| US6099561A (en) | 1996-10-21 | 2000-08-08 | Inflow Dynamics, Inc. | Vascular and endoluminal stents with improved coatings |
| ZA9710342B (en) | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
| US5980551A (en) | 1997-02-07 | 1999-11-09 | Endovasc Ltd., Inc. | Composition and method for making a biodegradable drug delivery stent |
| US6051276A (en) | 1997-03-14 | 2000-04-18 | Alpha Metals, Inc. | Internally heated pyrolysis zone |
| US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US5843172A (en) | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
| US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| PL337320A1 (en) | 1997-06-13 | 2000-08-14 | American Home Prod | Rapamycin preparations for oral administration |
| US5985325A (en) | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| JP2003524368A (ja) | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
| US5780604A (en) * | 1997-09-26 | 1998-07-14 | Abbott Laboratories | 11,12-cyclic phosphite or phosphate derivatives of erythromycin and related macrolides |
| US5972027A (en) | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
| US6031375A (en) | 1997-11-26 | 2000-02-29 | The Johns Hopkins University | Method of magnetic resonance analysis employing cylindrical coordinates and an associated apparatus |
| WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| US6623521B2 (en) | 1998-02-17 | 2003-09-23 | Md3, Inc. | Expandable stent with sliding and locking radial elements |
| US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
| US5980566A (en) | 1998-04-11 | 1999-11-09 | Alt; Eckhard | Vascular and endoluminal stents with iridium oxide coating |
| US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
| US8029561B1 (en) | 2000-05-12 | 2011-10-04 | Cordis Corporation | Drug combination useful for prevention of restenosis |
| EP1085846A2 (en) * | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
| US6087064A (en) | 1998-09-03 | 2000-07-11 | International Business Machines Corporation | Silsesquioxane polymers, method of synthesis, photoresist composition, and multilayer lithographic method |
| US6063101A (en) | 1998-11-20 | 2000-05-16 | Precision Vascular Systems, Inc. | Stent apparatus and method |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| DE60026513T2 (de) | 1999-05-27 | 2006-10-05 | Biocompatibles Uk Ltd., Farnham | Lokale arzneistoffabgabe |
| CA2374944A1 (en) | 1999-06-10 | 2000-12-21 | Nigel Hacker | Spin-on-glass anti-reflective coatings for photolithography |
| US6890448B2 (en) | 1999-06-11 | 2005-05-10 | Shipley Company, L.L.C. | Antireflective hard mask compositions |
| PT1189553E (pt) | 1999-06-24 | 2004-09-30 | Abbott Vascular Devices Ltd | Protese endovascular de balao expansivel |
| JP4187879B2 (ja) | 1999-08-06 | 2008-11-26 | 東京応化工業株式会社 | 感放射線レジスト組成物 |
| ES2219388T3 (es) | 1999-08-24 | 2004-12-01 | Ariad Gene Therapeutics, Inc. | 28-epi-rapalogos. |
| US6471979B2 (en) | 1999-12-29 | 2002-10-29 | Estrogen Vascular Technology, Llc | Apparatus and method for delivering compounds to a living organism |
| AU2599501A (en) | 1999-12-29 | 2001-07-09 | Advanced Cardiovascular Systems Inc. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
| WO2001049338A1 (en) | 1999-12-30 | 2001-07-12 | Li Wei Pin | Controlled delivery of therapeutic agents by insertable medical devices |
| WO2001052915A1 (en) | 2000-01-24 | 2001-07-26 | Biocompatibles Limited | Coated implants |
| WO2001087375A1 (en) | 2000-05-12 | 2001-11-22 | Cordis Corporation | Delivery devices for treatment of vascular disease |
| US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
| US20020013335A1 (en) | 2000-06-16 | 2002-01-31 | American Home Products Corporation | Method of treating cardiovascular disease |
| NZ523695A (en) | 2000-07-10 | 2004-07-30 | Univ Mississippi | Water-soluble polysaccharide preparations for pharmaceutical compositions and dietary supplements as immunotherapeutic compositions |
| JP4622061B2 (ja) | 2000-07-27 | 2011-02-02 | Ｊｓｒ株式会社 | レジスト下層膜用組成物およびその製造方法 |
| TW556047B (en) | 2000-07-31 | 2003-10-01 | Shipley Co Llc | Coated substrate, method for forming photoresist relief image, and antireflective composition |
| JP4141625B2 (ja) | 2000-08-09 | 2008-08-27 | 東京応化工業株式会社 | ポジ型レジスト組成物およびそのレジスト層を設けた基材 |
| PT1318837E (pt) | 2000-08-11 | 2004-12-31 | Wyeth Corp | Metodo de tratamenton de carcinoma positivo a receptor de estrogenio |
| JP2004509898A (ja) | 2000-09-19 | 2004-04-02 | ワイス | 水溶性ラパマイシンエステル |
| TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
| US20030033007A1 (en) * | 2000-12-22 | 2003-02-13 | Avantec Vascular Corporation | Methods and devices for delivery of therapeutic capable agents with variable release profile |
| US6471980B2 (en) | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
| GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| GB0100760D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| US20020119178A1 (en) | 2001-02-23 | 2002-08-29 | Luc Levesque | Drug eluting device for treating vascular diseases |
| IL157898A0 (en) | 2001-04-06 | 2004-03-28 | Wyeth Corp | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
| TW594416B (en) | 2001-05-08 | 2004-06-21 | Shipley Co Llc | Photoimageable composition |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| TW200306826A (en) | 2002-01-10 | 2003-12-01 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
| PL216224B1 (pl) * | 2002-02-01 | 2014-03-31 | Ariad Pharmaceuticals | Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie |
| US7432277B2 (en) * | 2002-02-01 | 2008-10-07 | Araid Gene Therapeutics, Inc. | Phosphorus-containing macrocycles |
| JP4557497B2 (ja) | 2002-03-03 | 2010-10-06 | ローム・アンド・ハース・エレクトロニック・マテリアルズ，エル．エル．シー． | シランモノマー及びポリマーを製造する方法及びそれを含むフォトレジスト組成物 |
| WO2004004644A2 (en) * | 2002-07-05 | 2004-01-15 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| WO2004010900A1 (en) * | 2002-07-25 | 2004-02-05 | Avantec Vascular Corporation | Devices delivering therapeutic agents and methods regarding the same |
| JP4502806B2 (ja) * | 2002-07-26 | 2010-07-14 | サムスン エレクトロニクス カンパニー リミテッド | 上部基板、これを有する液晶表示装置及びこれの製造方法 |
| CN100415233C (zh) | 2002-09-17 | 2008-09-03 | 惠氏公司 | 口服制剂 |
| WO2005016252A2 (en) * | 2003-07-11 | 2005-02-24 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing macrocycles |
| BRPI0413745A (pt) | 2003-08-18 | 2006-10-24 | Pfizer Prod Inc | horário mde dosagem para agentes anticancerìgenos erbb2 |
| AR045957A1 (es) | 2003-10-03 | 2005-11-16 | Novartis Ag | Composicion farmaceutica y combinacion |
| GB0327840D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| MX2007003790A (es) | 2004-09-30 | 2007-05-24 | Ariad Gene Therapeutics Inc | Metodo de tratamiento. |
| KR20070070184A (ko) | 2004-10-28 | 2007-07-03 | 와이어쓰 | 자궁근종의 치료에 있어서 ｍＴＯＲ 억제제의 용도 |
| EP1838288A4 (en) | 2004-12-20 | 2010-08-04 | Ariad Pharma Inc | THERAPEUTIC MATERIALS AND METHODS |
| US20060160837A1 (en) | 2004-12-29 | 2006-07-20 | The Brigham And Women's Hospital, Inc. | Rapamycin compounds in the treatment of neurofibromatosis type 1 |
| KR20070104908A (ko) | 2005-02-15 | 2007-10-29 | 와이어쓰 | 경구적으로 생체이용가능한 ｃｃｉ-779 정제 제형물 |
| US20070004767A1 (en) * | 2005-06-30 | 2007-01-04 | Gutmann David H | Methods for treating neurofibromatosis 1 |
| WO2007056117A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth | Antineoplastic combinations of temsirolimus and sunitinib malate |
| DE102010042183A1 (de) | 2010-10-08 | 2012-04-12 | Robert Bosch Gmbh | Hybridantriebseinrichtung |
| TWM483731U (zh) | 2013-12-31 | 2014-08-11 | Yong-Hua Chen | 辦公椅結構 |
| US9408008B2 (en) | 2014-02-28 | 2016-08-02 | Sonos, Inc. | Playback zone representations |
| US20160120174A1 (en) | 2014-10-29 | 2016-05-05 | Ronald Steven Cok | Imprinted multi-layer biocidal particle structure |
-
2003
- 2003-02-03 PL PL371526A patent/PL216224B1/pl unknown
- 2003-02-03 WO PCT/US2003/003030 patent/WO2003064383A2/en active Application Filing
- 2003-02-03 CA CA2472341A patent/CA2472341C/en not_active Expired - Fee Related
- 2003-02-03 DK DK03735110T patent/DK1478648T3/da active
- 2003-02-03 AU AU2003210787A patent/AU2003210787B2/en not_active Ceased
- 2003-02-03 CN CN200910149994.2A patent/CN101717410B/zh not_active Expired - Lifetime
- 2003-02-03 EA EA200700193A patent/EA011488B1/ru not_active IP Right Cessation
- 2003-02-03 EP EP20110180546 patent/EP2407473A3/en not_active Withdrawn
- 2003-02-03 IL IL16273403A patent/IL162734A0/xx unknown
- 2003-02-03 KR KR1020097022486A patent/KR101004224B1/ko active IP Right Grant
- 2003-02-03 ES ES03735110.3T patent/ES2485841T3/es not_active Expired - Lifetime
- 2003-02-03 KR KR20047011867A patent/KR100956195B1/ko active IP Right Grant
- 2003-02-03 EP EP20030735110 patent/EP1478648B1/en not_active Expired - Lifetime
- 2003-02-03 PT PT03735110T patent/PT1478648E/pt unknown
- 2003-02-03 JP JP2003564006A patent/JP4547911B2/ja not_active Expired - Lifetime
- 2003-02-03 US US10/357,152 patent/US20030220297A1/en not_active Abandoned
- 2003-02-03 EA EA200401008A patent/EA008379B1/ru not_active IP Right Cessation
- 2003-02-03 MX MXPA04007402A patent/MXPA04007402A/es active IP Right Grant
- 2003-02-03 CN CNB03807799XA patent/CN100522967C/zh not_active Expired - Lifetime
- 2003-02-03 BR BR0307544A patent/BR0307544A/pt not_active Application Discontinuation
- 2003-08-06 US US10/635,054 patent/US20040073024A1/en not_active Abandoned
-
2004
- 2004-06-04 US US10/862,149 patent/US7091213B2/en not_active Expired - Lifetime
- 2004-06-24 IL IL162734A patent/IL162734A/en active IP Right Grant
-
2006
- 2006-07-27 US US11/494,418 patent/US7186826B2/en not_active Expired - Lifetime
-
2007
- 2007-01-05 US US11/650,017 patent/US7709020B2/en not_active Expired - Lifetime
-
2009
- 2009-06-04 IL IL199153A patent/IL199153A/en active IP Right Grant
- 2009-07-20 AU AU2009202913A patent/AU2009202913B2/en not_active Ceased
-
2010
- 2010-04-06 US US12/798,501 patent/US8058426B2/en not_active Expired - Fee Related
-
2011
- 2011-11-14 US US13/295,826 patent/US9024014B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0307544A (pt) | Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos | |
| TR199901057T2 (US20030220297A1-20031127-C00074.png) | ||
| DOP2002000336A (es) | Inhibidores de benzotiadiazina de metaloproteinasas de la matriz | |
| GT200400076A (es) | Ligandos de receptores de cannabinoides y sus usos | |
| NO20092274L (no) | Ansamycinformuleringer og fremgangsmater for anvendelse derav | |
| BR0116452A (pt) | Composto, composição farmacêutica, uso de um composto | |
| EA200401204A1 (ru) | Сульфонилпроизводные в качестве новых ингибиторов гистон-деацетилазы | |
| NO20020809D0 (no) | Isomere sammenbundne pyrrolokarbazoler og isoindoliner | |
| MXPA05006568A (es) | Compuestos de pirazol aciclico para la inhibicion de proteina cinasa-2 activada por proteina cinasa activada por mitogenos. | |
| ATE37375T1 (de) | Phosphonyl-hydroxyacyl-aminosaeure-derivate und ihre verwendung als antihypertensiva. | |
| EA200501161A1 (ru) | Амино-1,3,5-триазины, которые n-замещены хиральным бициклическим радикалом, способ их получения, их композиции и их использование в качестве гербицидов и регуляторов роста растений | |
| DE69522692D1 (de) | Benzoyl derivate und ihre herstellung | |
| YU122891A (sh) | Postupak za dobijanje novog izolata trichoderma harzianum t-39, fungicidalnih jedinjenja | |
| DE60330376D1 (de) | Defructosylierungsverfahren | |
| NO20060417L (no) | Fremgangsmate til fremstilling av 1-okten fra krakk-C4 | |
| ATE264268T1 (de) | Verfahren zur herstellung von zsm-5 und zsm-11 | |
| DK0850231T3 (da) | Fremgangsmåde til fremstilling af en 2-chlor-5-chlormethyl-thiazolforbindelse | |
| ATE482933T1 (de) | Sulfopyrrolderivate | |
| DE50212185D1 (de) | Verfahren zur herstellung von isocyanaten | |
| Carmeli et al. | Revised structures and biosynthetic studies of tantazoles A and B | |
| ES2038740T4 (es) | Procedimiento de obtencion de compuestos guanidicos que comprenden un ion tetrafenilborato sustituido. | |
| RU94000725A (ru) | Производные 9н-имидазо (1,2-a) бензимидазол-3-ацетамида, способ их получения, фармацевтическая композиция на их основе и промежуточные соединения синтеза | |
| HUP9900114A2 (hu) | Szubsztituált N-metilén-tiokarbamid-származékok és ezeket tartalmazó kártevőírtó készítmények | |
| BR9916314A (pt) | Inibidores tricìclicos da proteìna farnesil transferase | |
| MX2007000061A (es) | Mezclas fungicidas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25C | Requirement related to requested transfer of rights |
Owner name: ARIAD GENE THERAPEUTICS, INC (US) Free format text: A FIM DE ATENDER A TRANSFERENCIA DE TITULAR SOLICITADA NA PETICAO NO 018090041547/SP DE 01/09/2009, QUEIRA O INTERESSADO APRESENTAR A LEGALIZACAO CONSULAR BRASILEIRA DE DOCUMENTO DE FUSAO APRESENTADO. |
|
| B25A | Requested transfer of rights approved |
Owner name: ARIAD PHARMACEUTICALS, INC. (US) Free format text: TRANSFERIDO POR FUSAO DE: ARIAD GENE THERAPEUTICS, INC. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. C07D 491/06; A61K 31/395; A61L 27/00; A61P 1/04, 11/00, 17/02, 17/04, 17/06, 19/02, 21/04, 25/00, 25/28, 27/02, 29/00, 3/10, 31/10, 35/00, 35/02, 37/00, 9/00, 9/10 Ipc: C07D 491/06 (2011.01), A61K 31/395 (2011.01), A61L |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 491/06 , A61K 31/395 , A61L 27/00 , A61P 1/04 , A61P 11/00 , A61P 17/02 , A61P 17/04 , A61P 17/06 , A61P 19/02 , A61P 21/04 , A61P 25/00 , A61P 25/28 , A61P 27/02 , A61P 29/00 , A61P 3/10 , A61P 31/10 , A61P 35/00 , A61P 35/02 , A61P 37/00 , A61P 9/00 , A61P 9/10 Ipc: A61K 31/395 (1974.07), A61K 31/661 (2000.01), A61K |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |